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Prednisolone pharmacokinetics in cushingoid and non-cushingoid kid-
ney transplant patients. Prednisolone pharmacokinetics and protein
binding have been compared in 16 cushingoid and 46 non-cushingoid
long-term kidney transplant recipients. After oral administration of 10
mg prednisolone, the cushingoid patients had a significantly higher peak
prednisolone serum conccentration (P < 0.03), a longer elimination
half-time (P < 0.03), and a larger area under the time-concentration
curve of total (P < 0.01) and free (P <0.03) prednisolone. The apparent
total body clearance of total and free prednisolone was significantly
lower in the cushingoid than in the non-cushingoid patients (P < 0.02
and < 0.05, respectively). There was no significant difference in time of
peak concentration, apparent volume of distribution or serum protein
binding of prednisolone. It is suggested that the development and
persistency of some cushingoid features may be related to a decreased
total body clearance of prednisolone, which, in turn, may be influenced
by impaired renal function.
Pharmacocinetique de Ia prednisolone chez des transplantés rénaux
cushingoides ou non cushingoides. La pharmacocinétique et la liaison
protéique de Ia prednisolone ont été comparée chez 16 receveurs
cushingoIdes et 46 receveurs non cushingoides et de greffons rénaux a
long terme. Aprs administration orale de 10 mg de prednisolone, les
malades cushingoides avaient un pic de concentration sérique de
prednisolone significativement plus élevé (P < 0,03), un temps de
demi-élimination plus long (P < 0,03), et une surface sous la courbe
temps-concentration de Ia prednisolone totale (P < 0,01) et libre (P <
0,03) plus grande. Les clearances corporelles totales apparentes de Ia
prednisolone totale et libre étaient significativement plus faibles chez
les malades cushingoides que chez les non cushingoIdes (P < 0,02 et P
< 0,05), respectivement. II n'y avait pas de difference significative
quant au moment du pic de concentration, au volume de distribution
apparent ou a la liaison de Ia prednisolone aux protCines seriques. Ii est
suggeré que le développement et Ia persistance de certaines
caracteristiques cushingoIdes pourraient être relies a une diminution de
Ia clearance corporelle totale de Ia prednisolone, laquelle peut étre
infiuencée par une alteration de Ia fonction rénale.
Patients treated with similar doses of glucocorticoids show
considerable variation in the incidence and severity of
cushingoid side effects. Variable glucocorticoid disposition has
been suggested as one possible explanation [1]. In two previous
studies, cushingoid patients were found to have a lower meta-
bolic clearance of prednisolone than non-cushingoid patients [1,
21, whereas no significant pharmacokinetic differences were
found in a third study [3]. These results may have been
influenced by the inclusion of heterogenous patient groups,
administration of different doses of prednisolone, and by differ-
ences in total steroid dose prior to the pharmacokinetic
investigation.
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In the present paper, we compare the pharmacokinetics and
protein binding of prednisolone in 16 cushingoid and 46 non-
cushingoid long-term kidney transplant recipients after oral
administration of 10 mg prednisolone.
Methods
One hundred and thirteen long-term kidney transplant recipi-
ents on a maintenance dose of 10 mg prednisolone (N = 58) or
prednisone (N = 55) gave their informed consent to participate
in a study of prednisolone pharmacokinetics. Each patient was
graded for clinical glucocorticoid toxicity by the degree of
cushingoid facial features (roundness, rubor, and acne) and skin
atrophy. Sixteen patients were classified by both observers
independently to assess between-observer difference. Skin at-
rophy was evaluated by feeling a skin-fold on the dorsum of the
forearm and by inspecting the patient for bruises and ec-
chymoses. The two features, each graded from 0 to 3, were
combined empirically to give a "cushing-score" from 0 to 5
(Table I). Based on these criteria, 46 patients were classified as
being non-cushingoid (Cushing-score 0 and 1) and 16 patients
were classified as being cushingoid (Cushing-score 4 and 5). As
shown in Table 1, we considered skin atrophy to be less specific
as a measure of glucocorticoid effect than the presence of
cushingoid facial features. Thus, some degree of skin atrophy
was allowed for non-cushingoid patients (Cushing score 1) as
long as they showed no cushingoid facial features.
The combination of facial and cutaneous cushingoid features
to give a Cushing-score, and the selection of groups to be
analyzed (0 and I vs. 4 and 5) were done prior to analysis of the
pharmacokinetic data.
After an overnight fast, all 113 patients received 10 mg
prednisolone orally as plain 5 mg tablets (Prednisolon NAF,
Olso, Norway) with 50 ml of water. Breakfast and other
medications were allowed after 1.5 hr. Blood samples were
drawn from an indwelling forearm vein cannula before tablet
administration, and after 0.5, 1, 1.5, 2, 4, 7, 9, 11, and 14 hr.
Serum was stored at — 20°C until analyzed.
Liver function tests (ASAT, ALAT, alkaline phosphatase,
and bilirubin), serum albumin, and a 12-hr creatinine clearance
were measured in all patients. Fasting serum cortisol concentra-
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Table 1. Grading of cushingoid facial features and skin atrophy in
kidney transplant recipients
Cushingoid facial features Skin atrophy
o = Not noticeable
= Mild
2 = Moderate
3 = Marked
o = Not noticeable, no bruising
1 = Mild thinning, no bruising2 = Moderate thinning, slight
bruising3 = Marked thinning, marked bruis-
ing and/or ecchymoses
Cushing score
Combination of cushingoid facial features and skin atrophy into "Cush-
ing score"
Skin atrophy
0 1 2 3 4 5
Cushingoid facial features 0 0 0 0 1 1 1 1 2 3 2 2 3 3 3
0 12 3012 310 231 23
30,000 cpmlml. One milliliter of serum was dialyzed against I ml
buffer for 3 hr (equilibrium was reached in less than 2.5 hr).
Serum and buffer (200 d) were added in duplicate to 4 ml
scintillation fluid and counted using an internal standard for
quench correction. The recovery of radioactivity from the
dialysis system was 100%.
Serum standards from pooled sera to which prednisolone 500
and 50 nglml had been added were included in each protein
binding assay. The fraction of free prednisolone at equilibrium
was 29.6% 0.47 for the 500 nglml standard and 12.3% 0.37
for the 50 ng/ml samples, giving a within-assay coefficient of
variation of 1.58 and 3.02%, respectively (N = 10). The
between-assay coefficients of variation were 3.33% (500 ng/ml)
and 6.16% (50 nglml) (N = 10). Serum protein concentrations
were measured in one sample from each patient before and after
equilibrium dialysis using a biuret method (A-Gent Total Pro-
tein Test, Abbott Laboratories Hospital Products Division,
North Chicago, Illinois, USA). The change in serum protein
concentration was used to calculate the volume change in the
serum compartment.
The concentration of total (free plus bound) prednisolone in
the serum compartment was corrected for dilution and loss of
drug to the buffer compartment by the Behm-Wagner equation
[6]:
A
(1)fbV + (1 — fb)(VO + V1)
where C equals the total concentration of drug in serum
compartment at equilibrium; A1 equals the total amount of drug
initially in the system; fb is the fraction of protein bound drug at
equilibrium; V1 is the volume of serum compartment at equilib-
rium; V0 is the volume of buffer compartment at equilibrium. To
calculate the free concentration of prednisolone in the original
serum samples, the observed free (C1) and bound (Cb) concen-
trations at equilibrium were fitted to the equation of Rocci and
Jusko [71:
(2)
where P(1), P(2), and P(3) equal parameters estimated by
nonlinear regression [8]. By means of this equation a time-
concentration curve for free prednisolone was estimated from
the original total serum concentrations.
The peak prednisolone concentration (Cmax) and the time of
Cmax(Tmax) were read directly from the experimental results.
The elimination half-time (tl/2) was determined by the formula
0.693/f3 with /3 as the apparent first-order disposition rate
constant calculated by linear least squares regression analysis
of the logarithms of the terminal 5 serum concentrations (Fig.
1). The area under the time-concentration curve of total (free
plus bound) prednisolone (AUCO) was measured by the trap-
ezoid rule extrapolated to infinity [9]. The area of free
prednisolone (AUCfree) was measured by the same method
using the calculated concentrations of free prednisolone in the
original serum samples. The proportion of free prednisolone
(Pfree) was obtained by AUCfree/AUCtot x 100. The apparent
0.87
total body clearance (Cli app) was calculated by dose x
(total and free) for total and free prednisolone, respectively, and
the apparent volume of distribution (VDapp) was calculated by:
tions were measured by radioimmunoassay (Immuchem 125 I
cortisol kit, Immuchem Corp., Carson, California, USA). Total
prednisolone concentrations were measured by a specific ra-
dioimmunoassay [4]. Serum (0.5 ml) was extracted twice with
ether (recovery 95%). The combined extracts were evaporated
to dryness under air at 40°C, and the residue was reconstituted
in 0.1 M phosphate buffer. A 0.5 ml sample, 0.1 ml anti-
prednisolone antibody (Guildhay Antisera, Guildford, England,
titer 1:2500) and 0.1 ml 3H-prednisolone (approximately 8500
cpm, spec act 40 Ci/mmole, The Radiochemical Centre,
Amersham, England) were incubated overnight at 4°C. Free
and bound prednisolone were separated by incubation with 0.1
ml freshly prepared dextran/charcoal suspension (Norit Grade
A, 1%, and Dextran 40.0000.1%) on ice for 5 mm, followed by
centrifugation at 4°C at x 5500g for 15 mm. The bound fraction
was decanted into counting vials, 10 ml of scintillation fluid
(Hydroluma, Lumac Systems, Basel, Switzerland) added, and
the samples were counted in a liquid scintillation counter
(Packard 3375, Packard Instruments, United Technology,
Downers Grove, Illinois, USA). The standard curve was gener-
ated from two separately weighed standards and consisted of
six points in the 80 to 15 ng/ml range. Plasma standards
containing 80, 50, and 15 ng prednisolone/ml were extracted and
analyzed with each assay. The mean within-batch coefficient of
variation was 3.7% (N = 10). The between-batch coefficients of
variation were 6.1, 6.4, and 16% (mean, 9.5%) for standards
containing 80, 50, and 15 ng prednisolone/ml, respectively (N =
20). The cross reactivity of the antibody was less than 4% for
cortisol.
Serum protein binding was measured in all post-dose sera by
equilibrium dialysis at 37°C [5] using the Dianorm apparatus
(Diachema AG, Zurich, Switzerland), cellulose membranes
with a molecular weight cut-off of 10,000 daltons, and isotonic
Krebs-Ringer phosphate buffers. Serum pH was measured in
one serum sample from each subject using an Astrup pH meter
before and after equilibrium dialysis (serum pH before dialysis:
8.14 0.27 (SD), and after: 7.35 0.09, N 30). Separate
experiments showed that the protein binding of prednisolone
did not vary measurably within a pH range of 7.2 and 7.6.
Prednisolone 3H, checked for purity (98%) by thin-layer
chromatography, was added to the buffer to give approximately
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The mean followup period since transplantation was more
than 5 years in both groups. Five cushingoid and two non-
cushingoid patients survived with their second transplant.
There was no statistically significant difference in mean total,
accumulated steroid dose (Table 3).
Fasting serum cortisol concentration was 11.4 6.5 j.g/dl in
the cushingoid patients (N = 14) and 10.8 6.8 tg/dl in the
non-cushingoid patients (N = 36, NS). Fasting cortisol concen-
trations were not available in two cushingoid and ten non-
cushingoid patients.
Prednisolone time-concentration curves after oral administra-
tion are shown in Figure 1. Compared to the non-cushingoid,
the cushingoid patients had a 9% higher Cmax (P < 0.03), an 11%
longer tio(P < 0.03), a 20% larger AUC0 (P < 0.01), and a 15%
larger AUCfreC (P < 0.03). The Cl app of total and free
prednisolone was 17% (P < 0.02) and 13% (P < 0.05), respec-
tively, lower in the cushingoid than in the non-cushingoid
patients. There was no significant difference in VDapp, Tmax, or
prednisolone protein binding, the Pfree being 16 2.4% in the
cushingoid and 16.5 3.4% in the non-cushingoid patients
(Table 4).
There were weak but statistically significant linear correla-
tions (P < 0.05) between creatinine clearance on the one hand
and Ci app of total prednisolone (r = 0.273) and tii2 (r = —0.286)
on the other (Figs. 2 and 3, N = 62).
Discussion
The results of the present investigation indicate that the
pharmacological effects of prenisolone may be significantly
influenced by individual differences in prednisolone
pharmacokinetics. Similar results have been reported in two
previous studies [1, 2]. Kozower, Veatch, and Kaplan [1] found
a longer ti,2 and a slower metabolic clearance of prednisolone in
six cushingoid than in seven non-cushingoid patients with
various diseases. Gambertoglio et al [2], in a study of six
cushingoid and six non-cushingoid kidney transplant patients,
found a significantly lower prednisolone Cl in the cushingoid
patients. Frey et al [3], however, found no statistically sig-
nificant differences in prednisolone pharmacokinetics between
14 cushingoid and 13 non-cushingoid patients and claimed that
the difference in cushingoid side-effects might be due to the
higher cortisol concentrations in the cushingoid patients. How-
ever, in the present study, and in the study by Gambertoglio et
al [2], there was no difference in fasting cortisol concentrations
between cushingoid and non-cushingoid patients.
In contrast to these studies, the present investigation was
done in long-term kidney transplant patients taking the same
steroid dose, and all were studied after administration of 10 mg
of prednisolone. The question of dose is important as the
pharmacokinetics of prednisolone are dose-dependent [5, 10,
11], and the use of different doses, as done in previous studies
[1—3], may influence the pharmacokinetic results. Further, the
mean accumulated steroid dose was comparable in both groups
(Table 3), which is important as the development of marked
cushingoid features may be due to a large previous steroid dose
rather than a decreased clearance of prednisolone. This may
apply to kidney transplant patients in particular, as they com-
monly receive several grams of prednisolone during a graft
rejection episode. The 13% difference (NS) between the present
patient groups in total accumulated steroid dose is unlikely to
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Fig. 1. Prednisolone time-concentration profiles in 16 cushingoid
(I—•—S) and 46 non-cushingoid (•--•--S) kidney transplant recipi-
ents after oral administration of prednisolone 10 mg. In this
semilogarithmic presentation, points represent means and vertical lines
1 SD. For visual clarity, only 1 SD is shown for each point.
Dose x 0.87 (0.87 0.14 = Absolute extent of
AUCO X /3
prednisolone bioavailability in 22 kidney transplant patients
after oral and intravenous administration of prednisolone (un-
published results).
To study the possible relationship between prednisolone
pharmacokinetics and pharmacodynamics, we compared the
pharmacokinetics of prednisolone in the 16 cushingoid patients
with those of the 46 non-cushingoid patients. Results are
presented as means 1 SD. Differences were tested for
statistical significance by the Wilcoxon test. A value of P < 0.05
was considered statistically significant.
Results
There was no statistically significant difference in Cushing-
scores given by the two observers either in the 16 patients
classified by both observers or in the total study population.
Nor was there any significant change in score distribution with
time during the 14 months of data collection for any of the
observers.
The cushingoid patients were older (56 6 vs. 44 14 years)
and contained more female patients (13 of 16) than the non-
cushingoid group (11 of 46). None of the patients used drugs
known to induce drug metabolizing enzymes. There was no
statistically significant difference in body weight, liver function
tests, or serum albumin concentration. Mean creatinine clear-
ance was 25% lower (P < 0.02) in the cushingoid than in the
non-cushingoid patients (Table 2).
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Table 2. Clinical details of cushingoid and non-cushingoid patients
N
Sex
FIM
Age
years
Body wt
kg
ALAT
JU
Bilirubin
p/liter
Albumin
giliter
C.
mi/mm
Cushingoid 16 11/5 56
6
71
11
22
9
12
4
40
2
67
25
Non-cushingoid 46 11/35 44
14
66
10
24
7
13
8
39
3
90
31
P <0.01 NS NS NS NS <0.02
Abbreviations: Ccr, clearance of creatinine; ALAT, (alanine amino transferase) SGPT.
Previous transplant Cushingoid Non-cushingoid
Number 5 2
Total (oral and i.v.) steroid
dose, mg 16820 9485 16630 8030
Present transplant
Number 16 46
Oral prednisolone dose,
mg 25971 6831 25560 8427
Methyl prednisolone dose
(i.v.), g
0 4 17
0.5to5 4 7
5.ltolO 7 17
>10 1 5
Total steroid dose, mg 30877 9038 30319 8864
Accumulated steroid
dose for both trans-
plants, mg 35602 10996 30847 9780
Months since transplant 66 23 64 28
influence the Cushing-score significantly. This difference is due
to the higher number of previous transplants in the cushingoid
group, as the steroid dose with the present transplant was
almost identical. Any effects of this difference are likely to be
reduced by a number of factors. Four of the five cushingoid
patients kept their first grafts only 1 to 6 months. Further, two
of these patients had no rejection of the present transplant, and
therefore received no intravenous methyl prednisolone. Also,
four of the five patients had 7.5 months (mean, range 4 to 11
months) without steroid treatment before the present trans-
plant, which would allow cushingoid features to regress. This
could also be the case in patient 5 in this group, as she was
treated with prednisone 5 mg/day for the last 6 months before
retransplantation.
In agreement with the findings of two previous investigations
[1, 2], our results suggest that differences in cushingoid side-
effects may be related to differences in prednisolone
pharmacokinetics. There was a preponderance of female pa-
tients in the cushingoid group, but it is not known whether
females are more sensitive to glucocorticoids than males,
although some side-effects, such as osteoporosis, may be more
pronounced in female patients. The higher mean age of the
cushingoid group suggests that glucocorticoid sensitivity may
increase with age. Indeed, there was a weak (r = 0.446) but
Table 3. Steroid dose and followup period in cushingoid and
non-cushingoid kidney transplant recipients (mean 1 sD)
E
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a The difference is not statistically significant.
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Fig. 2. Creatinine clearance (Car) and total body clearance (Cli app) of
total prednisolone in 16 cushingoid (0) and 46 non-cushingoid (•)
patients (r = 0.273, P < 0.05).
highly significant (P < 0.001) positive linear correlation be-
tween Cushing-score and age in the present patients, but there
was no statistically significant correlation between age and any
of the pharmacokinetic parameters.
Transplant function, as judged by creatinine clearance, was
poorer in the cushingoid than in the non-cushingoid patients.
Normally, up to 34% of an administered prednisolone dose may
be excreted unchanged in the urine within 24 hr [12]. In patients
with reduced renal function, renal elimination of prednisolone
and its metabolites is decreased [13]. Woo et a! [14] showed a
good linear correlation (r = 0.81) between the renal clearance
of prednisolone and creatinine clearance in kidney transplant
patients. Further, one of the present authors found a signifi-
cantly longer ti,2, lower Cli, and larger AUCO and AUCfree fl
uremic patients [15] and patients undergoing chronic
hemodialysis [16] than in healthy controls. Re-analysis of the
data provided by Gambertoglio et al [2] also suggests a relation-
ship between renal function and prednisolone pharmacokinet-
ics, as there was a positive linear correlation (r = 0.77, P <
0.01) between serum creatinine and prednisolone t'12 after
intravenous injection in the 12 transplant patients studied. A
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Table 4. Predinosolone pharmacokinetics and protein binding in 16 cushingoid and 46 non-cushingoid kidney transplant recipients after oral
administration of 10 mg of prednisolone
Cmax
nglml
Tmax
hr
T1/2
hr
AUC
tot
Cl1
mi/mm
free VDapp
liter
Pfr
%
tot
ng/mllhr
free
Cushingoid
I SD
431
65
1.1
0.5
3.57
0.51
2893
637
457
93
53
11
319
64
16.0
2.8
16.0
2.4
Non-cushingoid
1 SD
397
74
1.1
0.6
3.22
0.68
2421
581
397
113
63
15
367
67
17.1
3.4
16.5
3.4
P 0.03 NS 0.03 0.01 0.03 0.02 0.05 NS NS
Abbreviations: Cmax, peak prednisolone concentration; Tmax, time of peak prednisolone concentration; t'/2, prednisolone elimination half-time;
AUCIOI, area under the time-concentration curve of total prednisolone; AUCr, area under the time-concentration curve of free prednisolone;
Apparent Cl,, apparent total body clearance of total(tot) and free(free) prednisolone; Apparent VD, apparent volume of distribution; Pfr,
proportion of free prednisolone, calculated by AUCiree x ioo.
AUC,O,
by our own prednisolone bioavailability studies in 22 kidney
transplant patients with various degrees of cushingoid side-
effects (unpublished results). In our view, these results, to-
gether with the relatively large number of patients in both
groups, allow for the calculation of apparent VD and Ci after
oral administration, using f 0.87, which was the mean extent
of absolute bioavailability of oral prednisolone in 22 transplant
patients. However, as both clearance and volume are relative to
bioavailability, these parameters are expressed as apparent
values.
The present results suggest a relationship between certain
.• cushingoid side-effects and a decreased Cl app of prednisolone.
a The association between decreased creatinine clearance on the
one hand and a decreased prednisolone clearance and increased
glucocorticoid toxicity on the other (Fig. 2), suggest that the
biological effect of prednisolone may to some extent also
depend on renal function.
In our view, the present pharmacokinetic results suggest that
....'_—. dose reduction may be justified in patients with reduced Cl of
prednisolone. However, the possible gain for the patient from a
dose reduction must be carefully weighed against a possible
decrease in therapeutic effect.
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